Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-09-08 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于金宇生物技术股份有限公司2023年度向特定对象发行A股股票并在主板上市的补充法律意见书
Capital/Financing Update Classification · 95% confidence The document is a supplementary legal opinion letter issued by a law firm regarding a specific issuance of A shares by a company in 2023. It provides detailed legal confirmations and updates related to the issuance, including authorization, qualifications, business operations, assets, liabilities, governance, and other legal matters. The document references an original legal opinion letter and updates it for changes during a recent period. It is not a financial report, earnings release, or management discussion, nor is it a proxy statement or voting result announcement. It is a legal opinion related to a capital issuance. Given the content focuses on legal opinions and confirmations related to a capital raising event, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the report itself, not just an announcement or certification, so it is not RPA or RNS.
2023-09-08 Chinese
华泰联合证券有限责任公司关于金宇生物技术股份有限公司向特定对象发行股票之上市保荐书（2023年半年度财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to 金宇生物技术股份有限公司's 2023年度向特定对象发行A股股票 (2023 private placement of A shares) and listing on the main board of the Shanghai Stock Exchange. It contains detailed information about the issuer, business overview, financial data, risk factors, issuance details, pricing, number of shares, lock-up period, use of proceeds, and the role and commitments of the sponsor (华泰联合证券有限责任公司). The document is a formal sponsorship letter required for the issuance and listing process, which is a regulatory filing related to the issuance and listing of shares. It is not an annual report, earnings release, or other financial report. It is a detailed regulatory filing document related to capital raising and listing. Therefore, the most appropriate classification is "Capital/Financing Update (CAP)" as it concerns the issuance of shares and listing on the exchange.
2023-09-08 Chinese
金宇生物技术股份有限公司关于向特定对象发行A股股票募集说明书等相关文件财务数据更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (715 characters) regarding an update to financial data in a prospectus for a specific share issuance. It references the disclosure of a prospectus and updated financial data related to a targeted share issuance, pending regulatory approval. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the update and regulatory process. It is not a full financial report, earnings release, or detailed presentation. It fits the category of a Capital/Financing Update (CAP) because it concerns a specific share issuance and related financial data updates for fundraising purposes.
2023-09-08 Chinese
华泰联合证券有限责任公司关于金宇生物技术股份有限公司向特定对象发行股票之发行保荐书（2023年半年度财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a 2023 private placement of A shares by 金宇生物技术股份有限公司. It contains detailed information about the issuance, including the sponsor's commitments, internal review procedures, financial data, shareholder structure, and compliance with relevant laws and regulations. The document is a formal sponsorship letter issued by 华泰联合证券 as the lead underwriter and sponsor for the issuance. It is not a financial report like an annual or interim report, nor is it a simple announcement or voting result. It is a detailed regulatory filing related to capital raising and issuance sponsorship. Given the content and nature, this fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Therefore, the classification is CAP with high confidence.
2023-09-08 Chinese
金宇生物技术股份有限公司最近一年的财务报告及其审计报告以及最近一期的财务报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2022 of 金宇生物技术股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and extensive financial statement notes. The content includes audit procedures, accounting policies, financial statement disclosures, and detailed notes on financial instruments and credit loss provisions. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. There is no indication that this is an announcement or a certification letter; it is the actual audit report itself. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2022
2023-09-08 Chinese
金宇生物技术股份有限公司关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 half-year performance explanation meeting (业绩说明会) by 金宇生物技术股份有限公司. It references the previously disclosed 2023 half-year report but does not contain the report itself or substantive financial data. The document provides meeting time, location, participation methods, and contact information, indicating it is an announcement for an investor presentation event rather than the presentation or report itself. Given the nature of the content, it fits best under Investor Presentation (IP) as it is about a detailed presentation for investors focusing on financials and business results.
2023-09-08 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.